




1/44

**Figure 1****Red blood cell lysis in donor A after incubation  
with PMAA-Na in RPMI****Figure 1a****Red blood cell lysis in donor C after incubation  
with PMAA-Na in RPMI****Figure 1b**

2/44

**Figure 1 cont.****Figure 1c**

3/44


**Figure 2**

Figure 3

Lack of toxicity of PMAA-Na on primary human monocyte-derived-macrophages




Figure 3a

Lack of toxicity of PMAA-Na on primary human peritoneal macrophages




Figure 3b

Figure 4

Release of MIP-1 $\beta$  from human peritoneal macrophages by endotoxin free PMAA-Na (500  $\mu$ g/ml) after 36 h from a single donor A




Figure 4a

Release of MIP-1 $\beta$  from human peritoneal macrophages by endotoxin free PMAA-Na (500  $\mu$ g/ml) after 36 h from a single donor B




Figure 4b

Figure 4 cont.

Release of MIP-1 $\beta$  from human peritoneal macrophages by endotoxin free PMAA-Na (500  $\mu$ g/ml) after 36 h from a single donor C





Figure 4c


**Figure 5**

Release of TNF- $\alpha$  from human peritoneal macrophages by endotoxin free PMAA-Na (2,000  $\mu\text{g/ml}$ ) after 36 h from a single donor A



**Figure 5a**


Release of TNF- $\alpha$  from human peritoneal macrophages by endotoxin free PMAA-Na (500  $\mu\text{g/ml}$ ) after 36 h from a single donor B




**Figure 5b**

**Figure 6**


Release of chemokines and cytokines from single donor human peritoneal macrophages incubated with media control (□) or with PMAA-Na at 500 µg/ml (■) for 36 h



**Figure 6a**






**Figure 6b**



**Figure 6c**




9/44

**Figure 6 cont.****Figure 6d****Figure 6e****Figure 6f**


10/44

**Figure 7**

Release of MIP-1 $\beta$  from human monocyte derived macrophages by  
endotoxin free PMAA-Na after 36 h from a single donor A

**Figure 7a**


Release of MIP-1 $\beta$  from human monocyte derived macrophages by  
endotoxin free PMAA-Na after 36 h from a single donor B

**Figure 7b**

11/44


**Figure 7 cont.**

Release of MIP-1 $\beta$  from human monocyte derived macrophages by  
endotoxin free PMAA-Na after 36 h from a single donor C

**Figure 7c**


**Figure 8**

Release of MIP-1 $\beta$  from human peritoneal macrophages by PMAA-Na (500  $\mu$ g/ml) but not by commercially available PM AA-Na (500  $\mu$ g/ml) after 36 h from donor A



**Figure 8a**

Release of MIP-1 $\beta$  from human peritoneal macrophages by PMAA-Na (500  $\mu$ g/ml) but not by commercially available PM AA-Na (500  $\mu$ g/ml) after 36 h from donor A




**Figure 8b**


13/44

**Figure 9**

Release of TNF- $\alpha$  from human peritoneal macrophages by PMAA-Na (500  $\mu$ g/ml) but not by commercially available PM AA-Na (500  $\mu$ g/ml) after 36 h from donor A

**Figure 9a**


Release of TNF- $\alpha$  from human peritoneal macrophages by PMAA-Na (500  $\mu$ g/ml) but not by commercially available PM AA-Na (500  $\mu$ g/ml) after 36 h from donor A

**Figure 9b**


14/44

**Figure 10**


Red blood cell lysis in donor A after a 1 hour incubation in RPMI

**Figure 10a**

Red cell lysis in donor B after a 1 hour incubation in RPMI

**Figure 10b**


Red blood cell lysis in donor C after a 1 hour incubation in RPMI

**Figure 10c**


15/44

**Figure 11**


Red blood cell lysis in donor A after a 6 hour incubation in RPMI

**Figure 11a**

Red blood cell lysis in donor B after a 6 hour incubation in RPMI

**Figure 11b**


Red cell lysis in donor C after a 6 hour incubation in RPMI

**Figure 11c**


16/44

**Figure 12**


Red blood cell lysis in donor A after a 24 hour incubation in RPMI

**Figure 12a**

Red cell lysis in donor C after a 24 hour incubation in RPMI

**Figure 12b**

Red blood cell lysis in donor C after a 24 hour incubation in RPMI


**Figure 12c**



17/44

**Figure 13**


Red blood cell lysis in single donor after incubation with the amphotericin B - PMAA-Na preparation in RPMI




18/44

**Figure 14**

Lack of toxicity of the amphotericin B - PMAA-Na preparation  
after 1 day of culture with PBMN cells (n=3)

**Figure 14a**

Lack of toxicity of the amphotericin B - PMAA-Na preparation  
after 2 days of culture with PBMN cells (n=3)

**Figure 14b**

Lack of the toxicity of amphotericin B - PMAA-Na preparation  
after 6 days of culture with PBMN cells (n=2)


**Figure 14c**

Figure 15

Toxicity of the amphotericin B - PMAA-Na preparation after 2 days of culture with monocyte derived macrophages




Figure 15a

Toxicity of the amphotericin B - PMAA-Na preparation after 3 days of culture with monocyte derived macrophages




Figure 15b

Figure 16

Viability of *Leishmania mexicana* promastigotes after 2 days




Figure 16a

Viability of *Leishmania mexicana* promastigotes after 2 days




Figure 16b

21/44



**Figure 16 cont.****Figure 16c****Figure 16d**

Figure 17

Viability of Leishmania donovani promastigotes after 2 days




Figure 17a

Viability of Leishmania donovani promastigotes after 2 days






Figure 17b


23/44

**Figure 17 cont.****Figure 17c****Figure 17d**


24/44

**Figure 18**

**Inhibition of intracellular *Leishmania mexicana* amastigote growth by the amphotericin B-PMAA-Na preparation in human monocyte derived macrophages**

**Figure 18a**

**Inhibition of intracellular *Leishmania mexicana* amastigote growth by the amphotericin B-PMAA-Na preparation in human monocyte derived macrophages**


**Figure 18b**




25/44

**Figure 18 cont.**

**Inhibition of intracellular *Leishmania mexicana* amastigote growth by the amphotericin B-PMAA-Na preparation in human monocyte derived macrophages**

**Figure 18c**


**Inhibition of intracellular *Leishmania mexicana* amastigote growth by the amphotericin B-PMAA-Na preparation in human monocyte derived macrophages**

**Figure 18d**


26/44

**Figure 19**

**Inhibition of intracellular *Leishmania mexicana* amastigote growth  
by clinical grade amphotericin B in  
human monocyte derived macrophages**

**Figure 19a**


**Inhibition of intracellular *Leishmania mexicana* amastigote growth  
by Ambisome (Gilead Sciences) in  
human monocyte derived macrophages**

**Figure 19b**

27/44

**Figure 20**

**Inhibition of intracellular *Leishmania mexicana* amastigote growth in human macrophages by amphotericin B - PMAA-Na compared to AmBisome**




— amphotericin B - PMAA-Na  $IC_{50} = 0.3 \mu\text{g/ml}$   
..... AmBisome (Gilead Sciences):  $IC_{50} = 1.7 \mu\text{g/ml}$


28/44

**Figure 21**

**Inhibition of intracellular *Leishmania donovani* amastigote growth by the amphotericin B-PMAA-Na preparation in human monocyte derived macrophages**

**Figure 21a**


**Inhibition of intracellular *Leishmania donovani* amastigote growth by the amphotericin B-PMAA-Na preparation in human monocyte derived macrophages**

**Figure 21b**


29/44

**Figure 21 cont.**

**Inhibition of intracellular *Leishmania donovani* amastigote growth by the amphotericin B-PMAA-Na preparation in human monocyte derived macrophages**

**Figure 21c**


**Inhibition of intracellular *Leishmania donovani* amastigote growth by the amphotericin B-PMAA-Na preparation in human monocyte derived macrophages**

**Figure 21d**

30/44

**Figure 22**

**Inhibition of intracellular *Leishmania donovani* amastigote growth  
by clinical grade amphotericin B in  
human monocyte derived macrophages**

**Figure 22a**

**Inhibition of intracellular *Leishmania donovani* amastigote growth  
by Ambisome (Gilead Sciences) in  
human monocyte derived macrophages**



**Figure 22b**

Figure 23


Release of interferon- $\gamma$  from human peritoneal macrophages after culture with different compounds for 24 h




32/44

**Figure 24**

PBMC proliferation after 6 days incubation of the cells of donor A  
with the tuberculin PPD - PMAA-Na preparation

**Figure 24a**

PBMC proliferation after 5 days stimulation with antigen  
of the cells from donor B


**Figure 24b**



33/44

**Figure 25**


IFN- $\gamma$  production by human PBMCs  
that were stimulated with antigen from donor A for 24 h





34/44

**Figure 26**


Survival of *L. donovani* amastigotes in mouse liver macrophages after intravenous treatment with several different preparations of amphotericin B





35/44

**Figure 27****Lack of toxicity of PMAA-Na to single donor red blood cells (n=3)****Figure 27a****Figure 27b**

36/44

**Figure 27 cont.****Figure 27c**


37/44

**Figure 28****Lack of toxicity of PMAA-NA to single donor PBMCs after a 1 day incubation (n=3)****Figure 28a****Lack of toxicity of PMAA-NA to single donor PBMCs after a 2 day incubation (n=3)****Figure 28b**


38/44

**Figure 29**

**Lysis of red blood cells after incubation with amphotericin B - PMAA-Na  
stored as a lyophilised powder at 4°C for 4 months (n=2)**

**Figure 29a**


**Lysis of red blood cells after a 1 h incubation with amphotericin B - PMAA-Na  
stored in 5% dextrose at 4°C for 7 months**

**Figure 29b**


39/44

**Figure 30**

**Inhibition of *L. mexicana* amastigote growth in human MDMs  
after 3 d incubation with amphotericin B - PMAA-Na stored  
as a lyophilised powder at 4°C for 4 months**

**Figure 30a**


**Viability of *L. mexicana* promastigotes after 2 d incubation  
with amphotericin B - PMAA-Na stored in 5% dextrose at 4°C for 7 months**

**Figure 30b**


40/44

**Figure 31**

Inhibition of *C. neoformans* var *neoformans* clinical isolate 1 in monocyte derived macrophages after 3 days

**Figure 31a**

Inhibition of *C. neoformans* var *neoformans* NCPF 3003 growth in monocyte derived macrophages after 3 days


**Figure 31b**




41/44

**Figure 31 cont.**



Inhibition of *C. neoformans* var *gattii* clinical isolate growth in peritoneal macrophages after 3 days

**Figure 31c**

Inhibition of *C. neoformans* var *gattii* clinical in monocytes derived macrophages after 3 days

**Figure 31d**


42/44

**Figure 32****Figure 32a****Figure 32b**

43/44

**Figure 32 cont.**

Viability of *C.neoformans* var *gattii*  
NCPF 3216 after 3 days

**Figure 32c**

Viability of *C.neoformans* var *gattii*  
clinical isolate after 3 days


**Figure 32d**

Figure 33




Figure 33a




Figure 33b